SCIREQ to offer tremoFlo for preclinical research

Just in time for the upcoming ATS meeting in Denver, Colorado, we are excited to announce a worldwide exclusive distribution partnership with SCIREQ Scientific Respiratory Equipment Inc. to make the tremoFlo available for preclinical research.

SCIREQ possesses an in-depth knowledge of the needs and applications of scientists engaged in preclinical pulmonary research. Along with its parent company, emka Technologies, SCIREQ has access to an extensive worldwide distribution, service and support network that allows them to reach and provide outstanding service to researchers around the globe.

Unique Solutions for Translational Research

Together, SCIREQ and THORASYS can offer a unique solution permitting a new level of quantitative lung function assessment in late-stage preclinical research, including Safety Pharmacology. The specially adapted tremoFlo P-100 closes the gap between the clinically oriented tremoFlo C-100  and SCIREQ’s flexiVent system, now providing a continuous and coherent suite of products for translational pulmonary research from bench to bedside.

For further information, refer to the SCIREQ news release here. To enquire about the tremoFlo P-100, please contact SCIREQ via